Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

215 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma.
Batchelor TT, Duda DG, di Tomaso E, Ancukiewicz M, Plotkin SR, Gerstner E, Eichler AF, Drappatz J, Hochberg FH, Benner T, Louis DN, Cohen KS, Chea H, Exarhopoulos A, Loeffler JS, Moses MA, Ivy P, Sorensen AG, Wen PY, Jain RK. Batchelor TT, et al. Among authors: moses ma. J Clin Oncol. 2010 Jun 10;28(17):2817-23. doi: 10.1200/JCO.2009.26.3988. Epub 2010 May 10. J Clin Oncol. 2010. PMID: 20458050 Free PMC article. Clinical Trial.
Safety, Efficacy, and Biomarker Exploration in a Phase II Study of Bevacizumab, Oxaliplatin, and Gemcitabine in Recurrent Müllerian Carcinoma.
Horowitz NS, Penson RT, Duda DG, di Tomaso E, Boucher Y, Ancukiewicz M, Cohen KS, Berlin S, Krasner CN, Moses MA, Jain RK. Horowitz NS, et al. Among authors: moses ma. Clin Ovarian Cancer Other Gynecol Malig. 2011 Jun;4(1):26-33. doi: 10.1016/j.cloc.2011.04.003. Clin Ovarian Cancer Other Gynecol Malig. 2011. PMID: 21833345 Free PMC article.
A phase I trial and PK study of cediranib (AZD2171), an orally bioavailable pan-VEGFR inhibitor, in children with recurrent or refractory primary CNS tumors.
Kieran MW, Chi S, Goldman S, Onar-Thomas A, Poussaint TY, Vajapeyam S, Fahey F, Wu S, Turner DC, Stewart CF, Moses M, Packer RJ, Jakacki R, Banerjee A, Boyett JM, Fouladi M, Kun L. Kieran MW, et al. Childs Nerv Syst. 2015 Sep;31(9):1433-45. doi: 10.1007/s00381-015-2812-5. Epub 2015 Jul 19. Childs Nerv Syst. 2015. PMID: 26188774 Free PMC article. Clinical Trial.
Urinary VEGF and MMP levels as predictive markers of 1-year progression-free survival in cancer patients treated with radiation therapy: a longitudinal study of protein kinetics throughout tumor progression and therapy.
Chan LW, Moses MA, Goley E, Sproull M, Muanza T, Coleman CN, Figg WD, Albert PS, Ménard C, Camphausen K. Chan LW, et al. Among authors: moses ma. J Clin Oncol. 2004 Feb 1;22(3):499-506. doi: 10.1200/JCO.2004.07.022. J Clin Oncol. 2004. PMID: 14752073 Clinical Trial.
Urinary metalloproteinases: noninvasive biomarkers for breast cancer risk assessment.
Pories SE, Zurakowski D, Roy R, Lamb CC, Raza S, Exarhopoulos A, Scheib RG, Schumer S, Lenahan C, Borges V, Louis GW, Anand A, Isakovich N, Hirshfield-Bartek J, Wewer U, Lotz MM, Moses MA. Pories SE, et al. Among authors: moses ma. Cancer Epidemiol Biomarkers Prev. 2008 May;17(5):1034-42. doi: 10.1158/1055-9965.EPI-07-0365. Cancer Epidemiol Biomarkers Prev. 2008. PMID: 18483323
215 results